Rallybio Presents Results Of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially And Ethnically Diverse Populations
Portfolio Pulse from Benzinga Newsdesk
Rallybio Corporation (NASDAQ:RLYB) has presented results from a large-scale epidemiological analysis demonstrating the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT) across racially and ethnically diverse populations. The study suggests a significant increase in the number of pregnancies at higher risk for FNAIT annually, expanding the addressable market for RLYB212. Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant women at higher risk for FNAIT in the second half of 2024.
June 17, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rallybio's epidemiological analysis reveals a significant increase in pregnancies at higher risk for FNAIT, expanding the market for their RLYB212 therapy. The company is set to begin a Phase 2 dose confirmation study in 2H 2024.
The new data significantly expands the addressable market for RLYB212, which is positive for Rallybio's future revenue potential. The upcoming Phase 2 study further supports the company's progress and potential for successful product development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100